Atherosclerosis ID'd in Many Without CV Risk Factors
TUESDAY, Dec. 12, 2017 -- Many individuals without cardiovascular risk factors (CVRFs) have atherosclerosis, with low-density lipoprotein cholesterol (LDL-C) independently associated with the presence and extent of atherosclerosis, according to a study published in the Dec. 19 issue of the Journal of the American College of Cardiology.
Leticia Fernández-Friera, M.D., Ph.D., from the Centro Nacional de Investigaciones Cardiovasculares Carlos III in Madrid, and colleagues examined predictors of subclinical atherosclerosis in CVRF-free individuals. A total of 1,779 participants from the Progression of Early Subclinical Atherosclerosis study without conventional CVRFs (45.0 ± 4.1 years; 50.3 percent women) were assessed. A subgroup of 740 patients had optimal CVRFs.
The researchers found that 49.7 percent of CVRF-free participants had subclinical atherosclerosis (plaque or coronary artery calcification). In addition to male sex and age, LDL-C was independently associated with the presence and extent of atherosclerosis in the CVRF-free and CVRF-optimal groups (odds ratio, 1.14 to 1.18). The presence and extent of atherosclerosis was also associated with glycosylated hemoglobin levels in the CVRF-free group.
"Many CVRF-free middle-aged individuals have atherosclerosis. LDL-C, even at levels currently considered normal, is independently associated with the presence and extent of early systemic atherosclerosis in the absence of major CVRFs," the authors write. "These findings support more effective LDL-C lowering for primordial prevention, even in individuals conventionally considered at optimal risk."
© 2020 HealthDay. All rights reserved.
Posted: December 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.